2025-04-15 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis

**0. Summary of Key Figures:**

* **Cumulative Return (LLY):** 272.88%
* **Cumulative Return (VOO/S&P 500):** 66.69%
* **Return Difference (LLY vs. VOO):** 206.2%
* **Relative Return Difference:** 68.7% (This indicates LLY's performance is in the 68.7th percentile relative to its historical performance compared to the S&P 500.)
* **Current Price:** $754.35
* **RSI:** 31.10 (Suggests oversold conditions)
* **PPO:** -0.783 (Suggests bearish momentum)
* **Market Risk Indicator (MRI):** 0.4585 (Medium to High Risk)


**1. Company Overview and Performance Comparison:**

Eli Lilly and Co. is a global pharmaceutical company.  LLY has significantly outperformed the S&P 500 (VOO) over the analyzed period, with a cumulative return of 272.88% compared to VOO's 66.69%.  The substantial difference highlights LLY's strong performance. The relative return difference of 68.7% indicates LLY's recent performance is significantly above its historical average relative to the S&P 500.

**Alpha and Beta Analysis:**

The provided data shows consistently high CAGR (Compound Annual Growth Rate) for LLY across the analyzed periods, exceeding the market significantly.  While Beta fluctuates, it generally indicates higher volatility than the market (above 1).  Alpha is mostly positive, suggesting consistent outperformance relative to the market's risk-adjusted return.  The increasing market capitalization (Cap(B)) reflects LLY's growth over time.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 10.0% | 55.6% | -19.0% | 0.1 | 67.7 |
| 2016-2018  | 38.0% | 58.6% | 20.0% | -0.1 | 95.1 |
| 2017-2019  | 49.0% | 58.6% | 19.0% | 0.3 | 110.4 |
| 2018-2020  | 51.0% | 58.6% | 25.0% | 0.2 | 144.7 |
| 2019-2021  | 105.0% | 60.7% | 50.0% | 0.3 | 240.3 |
| 2020-2022  | 100.0% | 65.0% | 94.0% | 0.3 | 322.6 |
| 2021-2023  | 138.0% | 65.0% | 122.0% | 0.3 | 519.2 |
| 2022-2024  | 156.0% | 72.1% | 139.0% | 0.3 | 692.0 |
| 2023-2025  | 123.0% | 76.9% | 108.0% | 0.2 | 677.4 |


**2. Recent Price Movement:**

* **Closing Price:** $754.35
* **5-Day Moving Average:** $737.52
* **20-Day Moving Average:** $795.79
* **60-Day Moving Average:** $828.81

The current price is below all three moving averages, suggesting a possible downward trend in the short term.  The recent price increase of $3.0 (3.0% change) from the previous close shows a recent recovery/minor bounce,  but it is still trading below its recent average prices.


**3. Technical Indicators and Expected Return:**

* **RSI (31.10):**  Indicates the stock is oversold, potentially suggesting a bounce.
* **PPO (-0.783):** Shows negative momentum, aligning with the moving average analysis.
* **Relative Divergence Change (-2.2):**  Suggests a short-term bearish trend.
* **Expected Return (78.4%):**  This represents a significant potential outperformance against the S&P 500 over the long term (2+ years).  This high expected return should be viewed with caution and considered in the context of inherent risk, as high expected returns usually correlate with high-risk investment opportunities.
* **Market Risk Indicator (MRI) (0.4585):** Classifies the current market risk as medium to high.


**4. Recent Earnings Analysis:**

The earnings data shows some volatility. While Q2 2024 and Q3 2024 showed strong EPS and revenue, Q4 2023 and Q1 2024 were weaker.  It's important to look for trends and explanations behind this variation, possibly through press releases and financial reports.


| 날짜 | EPS | 매출 |
|---|---|---|
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2024-10-30 | -0.06 | 9.50 B$ |


**5. Financial Information:**

Revenue shows consistent growth, while profit margins remain high and stable.  Equity has increased overall, indicating strong financial health.  ROE (Return on Equity) is quite variable, suggesting potential fluctuations in profitability. Further investigation into the drivers of ROE variation would enhance the analysis.


Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |
| 2024-06-30 | $11.30B | 80.80% |
| 2024-03-31 | $8.77B | 80.91% |
| 2023-12-31 | $9.35B | 80.88% |

Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |
| 2024-06-30 | $13.56B | 21.88% |
| 2024-03-31 | $12.81B | 17.51% |
| 2023-12-31 | $10.77B | 20.33% |


**6. Overall Analysis:**

LLY has demonstrated exceptional historical performance, significantly outperforming the S&P 500.  However, recent price action suggests a potential short-term correction. The high expected return suggests long-term potential, but the medium-to-high market risk indicator and oversold RSI conditions warrant caution.  A deeper dive into the reasons for earnings volatility and ROE fluctuations is necessary for a more comprehensive assessment.  Before making any investment decisions, thorough due diligence including consideration of risk tolerance and diversification strategies is crucial.
